Stroke and cerebral ischaemia: Perspectives for clinical treatment and new drugs based on molecular pathophysiology

Pharmaceutical Journal

Volumn 256, Issue 6893, 1996, Pages 269-275

  Lees, George ^a   Anzal, Mohammed ^a  

^a ST MARY S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 PHOSPHONOALLYL) 2 PIPERAZINECARBOXYLIC ACID; 4 PHOSPHONOMETHYLPIPECOLIC ACID; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; ANCROD; APTIGANEL; BW 19C89; CPC 211; DEXTRORPHAN; ELIPRODIL; GANGLIOSIDE GM1; LIFARIZINE; LUBELUZOLE; MAGNESIUM; NEUROPROTECTIVE AGENT; NEW DRUG; NIMODIPINE; PIRACETAM; SELTOFEL; TIRILAZAD; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN INFARCTION; BRAIN ISCHEMIA; DRUG DESIGN; HUMAN; NONHUMAN; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; REVIEW; STROKE;

EID: 0030065226     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (123)

1. Hatano S. Experience from a multicentre stroke register: a preliminary report. Bull WHO 1976;54:541.
2. Warlow C. Disorders of the cerebral circulation. In: Walton J, editor. Brains diseases of the nervous system. Oxford: Medical Publications, 1993.
3. Bamford J, Dennis M, Sandercock P, Burn J, Warlow C. The frequency, causes and timing of death within 30 days of a first stroke: the Oxfordshire Community Stroke Project. J Neurol Neurosurg Psychiat 1990;52:824.
4. Fisher M, Jones S, Sacco RL. Prophylactic neuroprotection for cerebral ischaemia. Stroke 1994;25:1075-80
5. Counsell C, Sandercock P. The efficacy and safety of antiplatelet therapy in acute presumed ischaemic stroke: a systematic review of the randomized trials comparing immediate antiplatelet therapy with control. In Warlow C, Van Gijn J, Sandercock P, editors. Stroke module of the Cochrane database of systematic reviews. London: BMJ Publishing Group, 1995.
6. Counsell C, Sandercock P. The efficacy and safety of anticoagulant therapy in patients with acute presumed ischaemic stroke: a systematic review of the randomized trials comparing anticoagulants with control. In: Warlow C, Van Gijn J, Sandercock P, editors. Stroke module of the Cochrane database of systematic reviews. London: BMJ Publishing Group, 1995.
7. Secretary of State for Health. The health of the nation. London: HM Stationery Office, 1992.
8. Office of Population Censuses and Surveys. Review of the Registrar General on deaths by cause, sex and age in England and Wales. Series DH2, No 19. London: OPCS, 1992.
9. Dunbabin D. Cost-effective intervention in stroke. Pharmacoeconomics 1992;2:468-99.
10. Wardlaw J, Yamaguchi T, del Zoppo G, Hacke W. Thrombolysis in acute ischaemic stroke. In: Warlow C, Van Gijn J, Sandercock P, editors). Stroke module of the Cochrane database of systematic reviews. London. BMJ Publishing Group, 1995.
11. Stroke Unit Trialists' Collaboration. A systematic review of specialist multidisciplinary team (stroke unit) care for stroke inpatients. In: Warlow C. Van Gijn J, Sandercock P, editors. Stroke module of the Cochrane database of systematic reviews. London: BMJ Publishing Group, 1995.
12. Raichle ME. The pathophysiology of brain ischaemia. Ann Neurol 1983;13:2-10.
13. Eleff SM, Marcuki Y, Monsein LH, Traystman RT, Bryan RN, Koehle RC Na, ATP and intracellular pH transients during reversible complete ischaemia of dog cerebrum. Stroke 1991;22:233-41.
14. Pulsineili WA, Walman S, Rawlinson D, Plum F. Moderate hyperglycaemia augments ischaemic brain damage; A neuropathological study in the rat. Neurology 1982;32:1239-46.
15. Pulsinelli WA, Levy DE, Sigsbee B, Schrere P, Plum F. Increased damage after ischaemic stroke in patients with hyperglycaemia with or without diabetes mellitus. Am J Med 1983;74:540-44.
16. Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic-ischaemic brain damage. Ann Neurol 1986;19:105-11.
17. McBain CJ, Traynelis SF, Dingledine R. Regional variation of extracellular space in the hippocampus. Science 1990;249:674-6.
18. Schmidt-Kastner R, Freund TF. Selective vulnerability of the hippocampus in brain ischaemia. Neuroscience 1991;40:599-636.
19. Globus MYT, Busto R, Martinez E, Valdes I, Dietrich WD, Ginsberg MD. Comparative effect of transient global ischaemia on extracellular levels of glutamate, glycine and gamma-aminobutyric acid in vulnerable and nonvulnerable brain regions in the rat. J Neurochem 1991;57:470-7.
20. Garcia JH, Anderson ML. Physiopathology of cerebral ischaemia Crit Rev Neurobiol 1989;4:303-24
21. Heiss WD, Graf R. The ischaemic penumbra. Curr Opin Neurol 1994;7:11-9.
22. Hossmann KA. Glutamate mediated injury in focal cerebral ischaemia: the excitotoxin hypothesis revised. Brain Pathol 1994,4:23-36.
23. Heiss WD, Huber M, Fink GR et al Progressive derangement of peri-infarct viable tissue in ischaemic stroke J Cereb Blood Flow Metab 1992;12:193-203
24. Betz AL, Iannotti F, Hoff JT. Brain oedema a classification based on blood-brain barrier integrity. Cerebrovascular Brain Metab Rev 1989;1:133.
25. Matchar DB, Mc Crory DC, Barnett HJM, Feussner JR. Medical treatment for stroke prevention Ann Intern Med 1994; 121.41-53
26. Fisherman RA. Cerebrospinal fluid in diseases of the nervous system. Philadelphia: Saunders,1980.
27. De Courten Myers GM . Efficacious experimental stroke treatment with high dose methylprednisolone. Stroke 1994;25487-93.
28. Hall NC, Carney JM. Cheng MS, Butterfield DA. Ischaemia/reperfusion-induced changes in membrane proteins and lipids of gerbil cortical synaptosomes. Neuroscience 1995;64.81-9
29. Pauwels PJ, Van Assouw HP, Leysen JE. Attenuation of neurotoxicity following anoxia or glutamate receptor activation in EGF-and hippocampal extract-treated neuronal cultures. Cellular Signalling 1989,1:45-54.
30. Aitken PG , Jing J, Young J , Somjen GG. Ion channel involvement in hypoxia-induced spreading depression in hippocampal slices. Brain Res 1991;541:7-11.
31. Renkawek K, Lazarewicz JW. Protective effect of the calcium entry blocker nimodipme on cerebellar organotypic cultures submitted to anoxia. Neuropatol Pol 1989;27:323-9.
32. Freese A, DiFiglia M, Koroshetz WJ, Flint Beal M, Martin JB. Characterisation and mechanism of glutamate neurotoxicity in primary striatal cultures. Brain Res 1990;521:254-64.
33. Pauwels PJ, Van Assouw HP, Peters L, Moeremans M, Leysen JE. Chronic treatment with sabeluzole protects cultured rat brain neurons from the neurotoxic effects of excitatory amino acids. Synapse 1992;12.271-80.
34. 2+ channels. J Pharmacol Exp Ther 1990;255:1117-22.
35. Leach MJ, Swan JH, Eisenthal D, Dopson M, Nobbs M. BW619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage. Stroke 1993;27:1063-7
36. Ginsberg MD, Busto R. Rodent models of cerebral ischemia. Ibid 1989;20:1627-42
37. Karpiak SE, Tagliavia A, Wakade G. Animal models for the study of drugs in ischemic stroke. Ann Rev Pharmacol Toxicol 1989;29:403-12.
38. Neurologic disorders. In: Berkow R, Fletcher AJ, editors. The Merck Manual of Diagnosis and Therapy, 15th ed. Rahway, New Jersey. Merck & Co, 1987.
39. Edwards ME, Leach MJ, Lees G. Molecular mode of action of the neuroprotective agent BW619C89. Anesthesiology 1994;81:A857.
40. Smith SE, Lekieffre D, Sowinski P, Meldrum BS. Cerebroprotective effect of BW619C89 after focal or global cerebral ischemia in the rat. Neuropharmacol Neurotoxicol 1993,4:1339-42.
41. Malgouris C. Daniel M, Doble A. Neuroprotective effects of riluzole on N-methyl-D-aspartate-or veratridine-induced neurotoxicity in rat hippocampal slices. Neurosci Lett 1994;177:95-9.
42. Benoit E, Escande D. Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre. Eur J Physiol 1991;419:603-9.
43. 3H]aspartate release from cultured cerebellar granule cells. Neurosci Lett 1992;140:251-4.
44. Sheridan RD, Patmore L, Spedding M. The novel neuroprotective agent, RS-87476, potently inhibits sodium currents in mouse neuroblastoma Br J Pharmacol 1991;103(Suppl):26.
45. + currents in differentiated SH-SY5Y cells by lifarizine. Ibid 1994;113:600-6.
46. Lang DG, Ching Wang M, Cooper BR. Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuro blastoma cells. J Pharmacol Exp Ther 1993;266:829-34.
47. Wiard RP, Dickerson MC, Beek O, Norton R, Cooper BR. Neuroprotective properties of the novel antiepileptic lamotrigine in the gerbil model of global cerebral ischemia. Stroke 1995;26:466-72.
48. Rataud J, Debarnot F, Mary V, Pratt J, Stutzmann J-M. Comparative study of voltage-sentive sodium channel blockers in focal ischaemia and electric convulsions in rodents. Neurosci Lett 1994,172:19-23.
49. Lees G, Leach MJ. Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neuroglial cultures from rat cortex Brain Res 1993;612.190-9.
50. Yamasaki Y, Kogure K, Hara H, Ban H, Akaike N The possible involvement of teuodotoxin-sensitive ion channels in ischemic neuronal damage in the rat hippocampus. Neurosci Lett 1991;121:251-4.
51. Mackay KB, Kusumoto K, Graham DI, McCulloch J. Effect of the kappa-1 opioid agonist CI-977 on ischemic brain damage and cerebral blood flow after middle cerebral artery occlusion in the rat. Brain Res 1993;629:10-8.
52. Hayward NJ, McKnight AT, Woodruff GN. Neuroprotective effect of the kappa-agonist enadoline (CI-977) in rat models of focal cerebral ischaemia. Eur J Neurosci 1993;5:961-7.
53. Fujisawa H, Dawson D. Brown SE, MacKay KB, Bullock R, McCulloch J. Pharmacological modification of glutamate neurotoxicity in vivo. Brain Res 1993;629:73-8.
54. Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990;11:379-87
55. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995,26:503-13.
56. Novel therapies for stroke. Scrip 1994; (1940):27.
57. Nadler V, Mechoulam R, Sokolovsky M. The non-psychotropic cannabinoid (+)(3S,4S)-7-hydroxy-delta 6-tetrahydrocannabinol 1,1-dimethylheptyl (HU-21I) attenuates N-methyl-D-aspartate receptor-mediated neurotoxicity in primary cultures of rat forebrain. Neurosci Lett 1993;162.43-5.
58. 2+ influx through the Nmethyl-D-aspartate receptor ion channel by the non-psychoactive cannabinoid HU-211. Braid Res 1993;622.79-85.
59. Bullock R, Graham DI, Chan M-H, Lowe D, McCulloch J. Focal cerebral ischemia in the cat: Pretreatment with a competitive NMDA receptor antagonist, D-CPP-ene. J. Cereb Blood Flow Metab 1990,10:668-74.
60. Grotta J, Clark W, Coull B, Pettigrew LC, Mackay B, Goldstein LB, Meissner I, Murphy D, LaRue L. Safety and tolerability of the glutamate antagonist CGS 19755 (Seltofel) in patients with acute ischemic stroke Results of a phase IIa randomized trial. Stroke 1995;26:602-5.
61. Lodge D, Johnson KM. Noncompetitive excitatory amino acid receptor antagonists. Trends Pharmacol Sci 1990;11:81-6
62. New agents for ischaemic stroke. Scrip 1994,(1949):22.
63. Bucan AM, Lesiuk H, Barnes KA, LI H, Huang ZG, Smith KE, Xue D. AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists? Stroke 1993;24(Suppl 12):148-52.
64. Sheardown MJ, Nielsen E, Hansen AJ, Jacobsen P, Honore T. 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science 1990;247:571-4
65. Mosinger JL, Price MT, Bai HY, Xiao H, Wozniak DF, Olney JW. Blockade of both NMDA and non-NMDA receptors is required for optimal protection against ischemic neuronal degeneration in the in vivo adult mammalian retina. Exp Neurol 1991;113:10-17.
66. McManigle JE, Taviera DaSilva AM, Dretchen KL, Gillis RA. Potentiation of MK-801-induced breathing impairment by 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline. Eur J Pharmacol 1994;252:11-7.
67. Deberdt W, Interaction between psychological and pharmacological treatment in cognitive impairment. Life Sci 1994;55. 2057-66.
68. Enderby P, Broeckx J, Hospers W, Schildermans F, Debert W, Effect of piracetam on recovery and rehabilitation after stroke - a bouble blind, placebo-controlled study. Clin Neuropharmacol 1994; 17:320-31.
69. Millar RJ. Metabotrobic excitatory amino acid receptors reveal their true colors. Trends Pharmacol Sci 1991;12:365-7.
70. Cattaneo AD. Cerebral protection (editorial). Minerva Anestesiol 1993;59:403-17.
71. Pawlik G, Herholz K, Beil C, Remote effects of focal lesions on cerebral flow and metabolism. In. Heiss WD, editor. Functional mapping of the brain in vascular disease. Berlin: Springer-Verlag, 1986. pp59-83.
72. Schallen T, Jones TA, Linder MD. Multilevel transneuronal degeneration after brain damage. Behavioural events and effects of anticonvulsant gamma-aminobutyric acid-related drugs. Stroke 1990; 21(Suppl 11):III 143-6.
73. Cross AJ, Jones JA, Baldwin HA, Green AR, Neuroprotective activity of chlormethiazole following transient forebrain ischaemia in the gerbil. Br J Pharmacol 1991; 104:406-11.
74. Ogren SO, Chlormethiazole-mode of action Acta Psychiatr Scand 1986;73(no S329):13-27.
75. Abel MS, McCandless DW. Elevated gamma-aminobutyric acid levels attenuate the metabolic response to bilateral ischemia. J Neurochem 1992;58:740-4.
76. Prehn JH, Welsch M, Backhauss C, Nuglisch J, Ausmeier F, Karkoutly C, Krieglstein J Effects of serotonergic drugs in experimental brain ischemia: evidence for a protective role of serotonin in cerebral ischemia. Brain Res 1993;630:10-20.
77. Murphy KPSJ. Greenfield SA ATP-sensitive potassium channels counteract anoxia in neurones of the substanlia nigra. Exp Brain Res 1991;84:355-8.
78. + channels. Biol Neonate 1994;65: 160-5.
79. Decken J, Gleiter CH, Adenosme - an endogenous neuroprotective metabolite and neuromodutator. J Neural Transm [Suppl] 1994;43:23-31.
80. Dietrich WD, Miller LP, Prado R, et al. Acadesine reduces indium-labelled platelet deposition after photothrombosis of the common carotid artery in rats. Stroke 1995;26:111-6.
81. Park CK, Rudolphi KA, Anti-ischemic effects of propentofylline (HWA 285) against focal cerebral infarction in rats. Neurosa Lett 1994;178:235-8.
82. Ueno S, Miyauchi Y, Matsuda S, Endoh T. Effect of beraprost sodium (BPS) on the postischemic neuropathological changes and stroke index after left carotid artery occlusion in gerbils. Mol Chem Neuropathol 1994;23:137-43.
83. Nagasawa H, Araki T, Kogure K, Alteration of adenosme A1 receptor binding in the post-ischaermc rat brain. Neuroreport 1994;5:1453-6.
84. Zhang RL, Chopp M, Jiang N, et al. Antiintercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat. Stroke 1995;26:1438-43.
85. Chen H, Chopp M, Zhang RL, et al. AntiCD11B monoclonal-antibody reduces ischemic cell-damage. Ann Neurol 1994; 35:458-63.
86. Lindsberg PJ, Siren AL, Feuerstein GZ, Hallenbeck JM. Antagonism of neutrophil adherence in the deteriorating stroke model in rabbits. J Neurosurg 1995;82:269-77.
87. Sauter A. Rudin M. Calcium antagonists for reduction of brain damage in stroke. J Cardiovasc Pharmacol 1990;15(Suppl 1): S43-7.
88. Hulser PJ, Kornhuber AW, Kornhuber HH. Treatment of acute stroke with calcium antagonists. Eur Neurol 1990;30(Suppl 2): 35-41.
89. + channels involved in neuronal cell death. Protection by flunanzine. Life Sci 1991;48:1881-93.
90. McBurney RN, Daly D, Fischer JB, et al. New CNS-specific calcium antagonists. J Neurotrauma 1992;9(Suppl 2):531-43.
91. Twombly DA, Yoshii M, Narahashi T. Mechanisms of calcium channel block by phenytoin. J Pharmacol Exp Ther 1988; 246:189-95.
92. Alps BJ. Drugs acting on calcium channel: potential treatment for ischemic stroke. Br J Clin Pharmacol 1992;34.199-206.
93. Carolei A, Fieschi C, Bruno R, Toffano G. Monosialoganglioside GM1 in cerebral ischemia. Cerebrovasc Brain Metab Rev 1991;3.134-57.
94. Bartus RT, Baker KL, Heiser AD, et al. Postischemic administration of AK275, a calpain inhibitor, provides substantial protection against focal ischemic brain damage. J Cereb Blood Flow Metab 1994;14: 537-44.
95. Laizure SC, Franklin LK, Kaiser DG, et al. Disposition of trilazad (U74006F), a 21-aminosteroid, in the plasma, heart, brain, and the liver of the rat. Drug Metab Dispos 1993;21:951-4.
96. Thomas PD, Mao GD, Rabinovitch A, Poznansky MJ. Inhibition of superoxide-generating NADPH oxidase of human neutrophils by lazaroids (21-aminosteroids and 2-methylaminochromans). Biochem Pharmacol 1993;45:241-51.
97. Tuhrim S. Frontiers in the treatment of ischaemic stroke. Mt Sinai J Med (NY) 1993;60:295-8.
98. Jensen FE, Gardner GJ, Williams AP, Gallop PM, Aizenman E, Rozenberg PA. The putative essential nutrient pyrroloquinoline quinone is neuroprotective in a rodent model of hypoxic/ischemic brain injury. Neuroscience 1994;62:399-406.
99. Schmidley JN. Free radicals in central nervous system ischaemia. Stroke 1990;21: 1086-90.
100. Gruener N,Gross B, Gozian O, Barak M. Increase in Superoxide dismutase after cerebrovascular accident. Life Sci 1994;54: 711-3.
101. Garthwaite J. Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neural Sci 1991;14:60-7.
102. Buchan AM, Gertler SZ, Huang ZG, LI H, Chaundy KE, Xue D. Failure to prevent selective CA1 neuronal death and reduce cortical infarction following cerebral ischemia with inhibition of nitric oxide synthase. Neuroscience 1994;61:1-11.
103. Dawson DA, Graham DI, McCulloch J, Macrae IM. Anti-ischemic efficacy of a nitric oxide synthase inhibitor and a N-methyl-D-aspartate receptor antagonist in models of transient and permanent focal cerebral ischemia Br J Pharmacol 1994; 113:247-53.
104. Zhang F, White JG, Iadecola C. Nitric oxide donors increase blood flow and reduce brain damage in focal ischemia J Cereb Blood Flow Metab 1994;14:217-26.
105. Lipton SA, Choi YB, Pan Z-H, et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 1993;364:626-31.
106. Lesage AS, DeLoore KL, Osikowska-Evers B, Peelers L, Leysen JE. Lufaeluzole, a novel neuroprotectant inhibits the glutamate-activated NOS pathway. J Cereb Blood Flow Metab 1995;15(Supp 1):S432.
107. Rothman SM , Yamada KA, Lancaster N. Nordihydroguaiaretic acid attenuates NMDA neurotoxicity action beyond the receptor. Neuropharmacology 1993;32: 1279-88.
108. Dietrich WD. Alonso O, Busto R, Watson BD, Loor Y, Ginsberg MD. Influence of Amphetamine treatment on somatosensory function of the normal and infarcled rat brain. Stroke 1990;21(Suppl 11):III 147-50.
109. Synthelabo's strategic products. Scrip 1994;(1947) 13-14
110. CoCensys's stroke therapy in trials. Ibid 1995;(1997):27
111. Oczkowski WJ, Hachinski VC, Bogousslavsky J, Barnett HJ, Carruthers SG. A double-blind, randomized trial of PY108-068 in acute ischemic cerebral infarction. Stroke 1989;20:604-8.
112. Lees KR, Therapeutic interventions in acute stroke. Br J Clin Pharmacol 1992; 34:486-93.
113. Kaste M, Fogelholm R, Erila T, et al. A randomized double-blind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke. Stroke 1994;25:1348-53.
114. Fisher M, Grotta J. New uses for calcium channel blockers/therapeutic implications. Drugs 1993;46:961-75.
115. Fidia to concentrate on GM1. Scrip 1994; (1965):12.
116. Lenzi GL, Grigoletto F, Gent M, et al. Early treatment of stroke with monosialoganglioside GM-1. Stroke 1994;25 1552-57.
117. More studies needed with Upjohn's Freedox. Scrip 1994;(1964):21-2.
118. Enrolment suspended in Freedox trial. Ibid 1995;(1988/89):28.
119. Chan YW, Kay CS. Pentoxifylline in the treatment of acute ischaemic stroke - a reappraisal in Chinese stroke patients. Clin Exp Neurol 1993;30:110-6.
120. Ishchenko MM, Korol'kov AS. The effect of pentoxifylline on the systemic and cerebral hemodynamics in patients with circulatory encephalopathy and an atherosclerotic lesion of the precerebral arteries. Vrach Delo 1994;5-6:144-6
121. Bath P, Bath F. A systematic review of prostacychn and analogues in acute ischaemic stroke. In: Warlow C, Van Gijn J, Sandercock P, editors. Stroke module of the Cochrane Database of Systematic Reviews. London: BMJ Publishing Group, 1995.
122. Knoll begins phase III with Arvin in stroke Scrip 1994:(1928/29):24.
123. Cypros's stroke therapy to enter phase II Ibid 1994;(1988):23.